Search

Your search keyword '"Junghanss, Christian"' showing total 15 results
Start Over Author "Junghanss, Christian" Language undetermined
15 results on '"Junghanss, Christian"'

1. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Author

Jaramillo Segura, Sonia, Wass, Maxi, Schaffrath, Judith, Rieger, Kathrin, Nogai, Axel, Hänel, Mathias, Herbst, Regina, Stölzel, Friedrich, Röllig, Christoph, Jost, Edgar, Schlenk, Richard F., Noppeney, Richard, Brandts, Christian H., Krug, Utz, Götze, Katharina S., Buske, Sebastian, Florschütz, Axel, Schubert, Jörg, Opitz, Bernhard, Mohren, Martin, Eßeling, Eva, von Witzendorff, Stephan, Subklewe, Marion, Kaufmann, Martin, Frickhofen, Norbert, Scholz, Christian W., Schäfer-Eckart, Kerstin, Kunzmann, Volker, Schmidt-Hieber, Martin, Sayer, Herbert G., Rank, Andreas, Hemmati, Philipp, Schüler, Frank, Kowoll, Simone, Scheller, Marina, Steighardt, Jörg, Edemir, Bayram, Müller, Lutz Peter, Gliko-Kabir, Irit, Ludwig-Kraus, Beatrice, Edemir, Sabine, Sorani, Ella, Binder, Mascha, Vainstein, Abi, Kadosh, Shaul, Gromann, Cora, Wienke, Andreas, Baldus, Claudia D., Platzbecker, Uwe, Serve, Hubert, Bornhäuser, Martin, Junghanss, Christian, and Müller-Tidow, Carsten

Subjects
Immunology, ddc:610, Cell Biology, Hematology, Biochemistry
Published
2022

2. Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich, Stelljes, Matthias, Reményi, Péter, Wagner‐Drouet, Eva‐Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Labussiere‐Wallet, Hélène, Schaefer‐Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socié, Gérard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Jürgen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, Markiewicz, Miroslaw, and Rocca, Ursula La

Subjects
Leukemia, Myeloid, Acute, Transplantation Conditioning, Myelodysplastic Syndromes, Medizin, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Prospective Studies, Hematology, Middle Aged, Busulfan, Vidarabine, Aged
Abstract

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

Published
2022

3. Prognostic factors in non-small-cell lung cancer: insights from the German crisp registry

Author

Griesinger, Frank, Hummel, Horst-Dieter, Schäfer, Harald, de Wit, Maike, Kaiser, Ulrich, Kern, Jens, Jänicke, Martina, Spring, Lisa, Zacharias, Stefan, Kaiser-Osterhues, Anja, Groth, Annika, Hipper, Annette, Zaun, Gregor, Müller, Lothar, Uhlig, Jens, Thomas, Michael, Sebastian, Martin, Eberhardt, Wilfried, Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig, Carla Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kamal, Haytham, Kambartel, Kato, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt, Peter Florian, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, and Zeth, Matthias

Subjects
Pulmonary and Respiratory Medicine, Medizin
Abstract

IntroductionUnderstanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care.MethodsPrognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models.ResultsCurrent M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, pConclusionIn this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance.

Published
2022

4. sj-docx-2-pmj-10.1177_02692163221099114 – Supplemental material for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan)

Author

Klinger, Isabell, Heckel, Maria, Shahda, Sophie, Kriesen, Ursula, Schneider, Carolin, Kurkowski, Sandra, Junghanss, Christian, and Ostgathe, Christoph

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110308 Geriatrics and Gerontology
Abstract

Supplemental material, sj-docx-2-pmj-10.1177_02692163221099114 for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan) by Isabell Klinger, Maria Heckel, Sophie Shahda, Ursula Kriesen, Carolin Schneider, Sandra Kurkowski, Christian Junghanss and Christoph Ostgathe in Palliative Medicine

Published
2022
Full Text
View/download PDF

5. sj-doc-1-ict-10.1177_15347354221143064 – Supplemental material for Association Between Cancer-Related Fatigue and Falls in Patients With Myeloproliferative Neoplasms: Results of a Multicenter Cross-Sectional Survey From the East German Study Group for Hematology and Oncology (OSHO #97)

Author

Felser, Sabine, Gube, Martin, Gruen, Julia, Coutre, Philipp Ie, Schulze, Susann, Muegge, Lars-Olof, Junghanss, Christian, and Ulbricht, Sabina

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110306 Endocrinology, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-doc-1-ict-10.1177_15347354221143064 for Association Between Cancer-Related Fatigue and Falls in Patients With Myeloproliferative Neoplasms: Results of a Multicenter Cross-Sectional Survey From the East German Study Group for Hematology and Oncology (OSHO #97) by Sabine Felser, Martin Gube, Julia Gruen, Philipp Ie Coutre, Susann Schulze, Lars-Olof Muegge, Christian Junghanss and Sabina Ulbricht in Integrative Cancer Therapies

Published
2022
Full Text
View/download PDF

6. sj-docx-1-pmj-10.1177_02692163221099114 – Supplemental material for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan)

Author

Klinger, Isabell, Heckel, Maria, Shahda, Sophie, Kriesen, Ursula, Schneider, Carolin, Kurkowski, Sandra, Junghanss, Christian, and Ostgathe, Christoph

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110308 Geriatrics and Gerontology
Abstract

Supplemental material, sj-docx-1-pmj-10.1177_02692163221099114 for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan) by Isabell Klinger, Maria Heckel, Sophie Shahda, Ursula Kriesen, Carolin Schneider, Sandra Kurkowski, Christian Junghanss and Christoph Ostgathe in Palliative Medicine

Published
2022
Full Text
View/download PDF

7. sj-docx-1-pmj-10.1177_02692163221099114 – Supplemental material for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan)

Author

Klinger, Isabell, Heckel, Maria, Shahda, Sophie, Kriesen, Ursula, Schneider, Carolin, Kurkowski, Sandra, Junghanss, Christian, and Ostgathe, Christoph

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110308 Geriatrics and Gerontology
Abstract

Supplemental material, sj-docx-1-pmj-10.1177_02692163221099114 for COVID-19: Challenges and solutions for the provision of care to seriously ill and dying people and their relatives during SARS-CoV-2 pandemic – perspectives of pandemic response team members: A qualitative study on the basis of expert interviews (part of PallPan) by Isabell Klinger, Maria Heckel, Sophie Shahda, Ursula Kriesen, Carolin Schneider, Sandra Kurkowski, Christian Junghanss and Christoph Ostgathe in Palliative Medicine

Published
2022
Full Text
View/download PDF

8. Additional file 8 of Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo

Author

Richter, Anna, Sender, Sina, Lenz, Annemarie, Schwarz, Rico, Hinz, Burkhard, Knuebel, Gudrun, Sekora, Anett, Escobar, Hugo Murua, Junghanss, Christian, and Roolf, Catrin

Abstract

Additional File 8: Figure S5. Original blots for Fig. 3b, c, S2, S3. Red boxes indicate the regions used in the respective Figures.

Published
2020
Full Text
View/download PDF

9. Additional file 1 of Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania

Author

Grunwald, Luise, Grosse-Thie, Christina, Sender, Sina, Knuebel, Gudrun, Krohn, Saskia, Roolf, Catrin, Junghanss, Christian, Henze, Larissa, and Escobar, Hugo Murua

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2020
Full Text
View/download PDF

11. Additional file 3 of Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo

Author

Richter, Anna, Sender, Sina, Lenz, Annemarie, Schwarz, Rico, Hinz, Burkhard, Knuebel, Gudrun, Sekora, Anett, Escobar, Hugo Murua, Junghanss, Christian, and Roolf, Catrin

Subjects
sense organs, skin and connective tissue diseases
Abstract

Additional File 3: Table S2. Gene expression fold changes of genes involved in apoptotic processes.

Published
2020
Full Text
View/download PDF

15. Additional File 11

Author

Richter, Anna, Roolf, Catrin, Hamed, Mohamed, Gladbach, Yvonne, Sender, Sina, Konkolefski, Christoph, KnĂźbel, Gudrun, Sekora, Anett, Fuellen, Georg, Vollmar, Brigitte, Escobar, Hugo Murua, and Junghanss, Christian

Abstract

Table S9. Influence of CX and DEC on PTEN and CK2 promoter methylation beta values and respective fold changes (FC). (DOCX 14 kb)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results